Szostak, B. et al. 2025. Overview of available treatment and new drug action points in obesity pharmacology. Will GIP, glucagon, amylin replace GLP-1?. Prospects in Pharmaceutical Sciences. 23, 2 (May 2025), 42–49. DOI:https://doi.org/10.56782/pps.361.